In a report released today, Miki Sogi from Bernstein maintained a Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report), with a price target of Yen4,500.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Miki Sogi’s rating is based on a combination of factors affecting Takeda Pharmaceutical Co’s current and future performance. The company is actively managing challenges related to US tariffs and the 340B program, which significantly impact their financial outlook. Takeda is implementing mitigation strategies such as inventory adjustments and potential shifts to US manufacturing to counteract these pressures.
Additionally, while Takeda is preparing for new product launches, the company faces uncertainties in pricing dynamics, particularly concerning Medicare and Medicaid. The commercial segment, which constitutes a significant portion of their revenue, could be affected by changes in Medicare pricing. Despite these challenges, Takeda is investing in efficiency programs to support future growth, but these efforts have led to a Hold rating, reflecting a balanced view of opportunities and risks.